METABOLIC DYSFUNCTION

Global epidemiology of nonalcoholic fatty liver disease

1. WHO Fact Sheet on Obesity and Overweight. October 2017

DIABETIC EYE DISEASE

- Diabetic retinopathy is the leading cause of new cases of blindness in the working-age population.
- It involves a progressive deterioration of the blood vessels in the retina.

Type 2 Diabetes

- Affects 425 million people worldwide.
- 1 in 10 adults is estimated to have type 2 diabetes.
- Complications include increased incidence of cardiovascular disease, kidney disease, lower limb amputations, and death.

FIBROSIS

- In 2030, nearly 2 billion adults will have type 2 diabetes.
- About 17% of the world’s adult population were overweight or obese.

Obesity & Overweight

- 1 in 10 adults is estimated to have type 2 diabetes.
- 4 in 10 adults with type 2 diabetes are obese.

REFERENCES

1. WHO Fact Sheet on Obesity and Overweight. October 2017

DIGITAL DIABETES

- Diabetes harms both the leading causes of vision loss in adults.
- More than half of patients with type 2 diabetes have diabetic retinopathy.

DISEASE NETWORKS

- More than half of patients with type 2 diabetes are obese.

INFLAMMATION

- Our holistic approach gives us the opportunity to explore a number of different research fields, allowing us to prioritize the most promising avenues of discovery, as we pursue the next key discoveries.
- By exploring disease mechanisms and common pathways, we aim to create synergies across multiple conditions connected by underlying similar pathologies.
- Our research approach directed towards the molecular foundations of these conditions and in collaboration with academia, biotech, and pharma, is exploring new therapeutic compounds for the treatment of obesity and type 2 diabetes.

Our Research in Fibrosis

- We are committed to accelerating research in fibrosis, aiming to develop new and improved strategies to address the significant unmet medical need in this area.

Our Research in Cardiometabolic Disease Research and Development

- We are committed to creating synergies across diseases, we aim to create synergies across multiple indications.
- By exploring disease mechanisms and common pathways, we aim to create synergies across multiple conditions connected by underlying similar pathologies.

Why we need a patient-centric approach to Cardiometabolic Disease Research and Development

Patients with cardiometabolic diseases often have multiple conditions connected by underlying similarities.

Our Research in Metabolic Dysfunction

- We are committed to understanding how inflammation leads to fibrosis.
- We are harnessing the power of our disease networks to investigate the molecular foundations of these conditions and in collaboration with academia, biotech, and pharma, are exploring new therapeutic compounds for the treatment of obesity and type 2 diabetes.

Our Research in Inflammation

- We are committed to understanding how inflammation leads to fibrosis.
- We are harnessing the power of our disease networks to investigate the molecular foundations of these conditions and in collaboration with academia, biotech, and pharma, are exploring new therapeutic compounds for the treatment of obesity and type 2 diabetes.

Putting patients at the heart of innovation in Cardiometabolic Disease Research and Development